Adam S. Kibel
A5072104844- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Urological Disorders and Treatments
- Genetic Associations and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Hormonal and reproductive studies
- Urologic and reproductive health conditions
- Colorectal Cancer Screening and Detection
- Epigenetics and DNA Methylation
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Cardiac, Anesthesia and Surgical Outcomes
- Genetic factors in colorectal cancer
- Urinary Bladder and Prostate Research
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
Brigham and Women's Hospital
2016-2025
Harvard University
2016-2025
Dana-Farber Brigham Cancer Center
2016-2025
Dana-Farber Cancer Institute
2016-2025
Massachusetts General Hospital
2016-2024
City Of Hope National Medical Center
2024
Stanford University
2024
The University of Texas Southwestern Medical Center
2014-2024
City of Hope
2024
The University of Texas Health Science Center at San Antonio
2024
We sought to identify determinants of health-related quality life after primary treatment prostate cancer and measure the effects such on satisfaction with outcome in patients their spouses or partners.
Germ-line mutations of the von Hippel-Lindau tumor suppressor gene ( VHL ) predispose individuals to a variety human tumors, and somatic this have been identified in sporadic renal cell carcinomas cerebellar hemangioblastomas. Two transcriptional elongation factors, Elongin B C, were shown bind vitro vivo short, colinear region protein (pVHL) that is frequently mutated tumors. A peptide replica inhibited binding pVHL whereas point-mutant derivative, corresponding naturally occurring missense...
<h3>Context</h3>Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction erectile dysfunction treatment are lacking.<h3>Objective</h3>To predict long-term following based on individual patient and characteristics.<h3>Design</h3>Pretreatment characteristics, sexual HRQOL, details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes...
This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.A systematic review and meta-analysis literature was conducted using controlled vocabulary supplemented keywords relating relevant concepts castration resistance. The search strategy developed executed by reference librarians methodologists create an evidence report limited English-language, peer-reviewed literature....
Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for overdiagnosis low-risk underdiagnosis high-grade prostate cancer. To improve early-detection biopsy decisions, National Cancer Institute conducted prospective validation trial to assess diagnostic performance cancer 3 (PCA3) urinary assay detection among men screened with PSA.
In advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results in a high response rate, less toxicity, few dosing delays. We explored the efficacy safety of neoadjuvant ddMVAC pegfilgrastim support muscle-invasive cancer (MIUC).
Prostate cancer (CaP) is the leading among men of African descent in USA, Caribbean, and Sub-Saharan Africa (SSA). The estimated number CaP deaths SSA during 2008 was more than five times that Americans expected to double by 2030. We summarize publicly available data collected from Carcinoma (MADCaP) Consortium Caribbean Cancer (AC3) evaluate incidence mortality worldwide. are highest USA Caribbean. Tumor stage grade were SSA. report a higher proportion T1 prostate tumors countries with...
BACKGROUND Breast cancer 2 ( BRCA2 )‐associated breast and ovarian cancers are sensitive to platinum‐based chemotherapy. It is unknown whether ‐associated prostate responds favorably such treatment. METHODS A retrospective analysis of a single‐institution cohort men with castration‐resistant, metastatic was performed determine the association between carrier status pathogenic germline variants prostate‐specific antigen response carboplatin‐based From 2001 through 2015, 8081 adult who had...
Abstract It remains elusive whether some of the associations identified in genome-wide association studies prostate cancer (PrCa) may be due to regulatory effects genetic variants on CpG sites, which further influence expression PrCa target genes. To search for sites associated with risk, here we establish models predict methylation (N = 1,595) and conduct analyses risk (79,194 cases 61,112 controls). We identify 759 showing an association, including 15 located at novel loci. Among those 42...
The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion local options as well those hormone-sensitive prostate cancer. Please refer II discussion management castration-resistant disease.The systematic review utilized inform this guideline was conducted by an independent...
Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment.To develop standard set of multidimensional patient-centered for tracking, comparing, improving localized prostate cancer (PCa) treatment value.We convened an international working group patients, registry experts, urologists, radiation oncologists review existing data practices.The defined recommended representing who should be tracked, what measured at time points, are necessary...
Given the lack of randomized trials comparing robot-assisted radical prostatectomy (RARP) and open (ORP), we sought to re-examine outcomes these techniques using a cohort patients treated in postdissemination era.Overall, data from 5,915 with prostate cancer RARP or ORP within SEER-Medicare linked database diagnosed between October 2008 December 2009 were abstracted. Postoperative complications, blood transfusions, prolonged length stay (pLOS), readmission, additional therapies, costs care...